Defective genes account for∼ 80% of the total of more than 7,000 diseases known to date.
Gene therapy brings the promise of a one-time treatment option that will fix the errors in …

Triple-negative breast cancer (TNBC) is the most aggressive, prevalent, and distinct subtype
of breast cancer characterized by high recurrence rates and poor clinical prognosis, devoid …

Recent progress in gene transfer technology enables the delivery of genes precisely to the
application-relevant cell type ex vivo on cultivated primary cells or in vivo on local or …

The demand for therapeutic biologics has rapidly grown over recent decades, creating a
dramatic shift in the pharmaceutical industry from small molecule drugs to biological …

Highlights•Engineering of AAV capsids optimizes efficiency and/or specificity of gene
transfer.•High throughput-selection of AAV libraries identifies AAV variants with novel …

Triple negative breast cancer (TNBC) is characterised by the lack of receptors for estrogen
(ER), progesterone (PR), and human epidermal growth factor 2 (HER2). Since it cannot be …

Breast cancer (BC) is considered one of the most frequent cancers among woman
worldwide. While conventional therapy has been successful in treating many cases of breast …

Viral vectors can generate high levels of recombinant protein expression providing the basis
for modern vaccine development. A large number of different viral vector expression systems …

Safe and effective gene therapy approaches require targeted tissue-specific transfer of a
therapeutic transgene. Besides traditional approaches, such as transcriptional and …

MicroRNAs (miRNAs) constitute a subclass of non-coding RNAs that exert substantial
influence on gene-expression regulation. Their tightly controlled expression plays a pivotal …